GlassScriptPhysician profile
Michele Lynn Raymond
NPI 1689641557
$23,513.17
in general payments reported to CMS, 2019-2025
62 companies · $4,125 in 2025
The $4,125 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,721 · 2020: $2,759 · 2021: $4,053 · 2022: $3,576 · 2023: $3,459 · 2024: $2,820 · 2025: $4,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,396.68 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,972.67 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $2,237.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,105.46 | 2019-2025 | |
| Lilly USA, LLC | $1,578.37 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,421.58 | 2019-2025 | |
| Amgen INC. | $1,386.04 | 2019-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $1,081.61 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Teva Pharmaceuticals USA, INC. | $881.42 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Merck Sharp & Dohme LLC | $782.61 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $762.87 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $731.24 | 2021-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $591.19 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $572.76 | 2019-2025 | Xifaxan |
| Vanda Pharmaceuticals INC. | $533.12 | 2019-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $411.66 | 2022-2025 | Rexulti |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $406.74 | 2019-2025 | Spravato |
| Allergan, INC. | $379.93 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $347.68 | 2019-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $347.27 | 2019-2023 | |
| Mylan Specialty L.P. | $330.12 | 2020-2024 | Yupelri, Yupelri |
| Alkermes, INC. | $301.35 | 2022-2025 | Lybalvi |
| Axsome Therapeutics, INC. | $291.19 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $234.42 | 2022-2024 | Quviviq |
| Abbott Laboratories | $221.99 | 2019-2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $221.70 | 2019-2022 | |
| Lundbeck LLC | $212.47 | 2022-2025 | Rexulti, Vyepti |
| Biohaven Pharmaceuticals, INC. | $204.28 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $196.65 | 2019-2025 | Eliquis |
| Astellas Pharma US INC | $163.31 | 2019-2021 | |
| Eisai INC. | $128.71 | 2019-2024 | |
| Paratek Pharmaceuticals, INC. | $119.30 | 2022-2025 | Nuzyra |
| Exact Sciences Corporation | $109.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $103.13 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $102.47 | 2024-2025 | Gemtesa |
| Corcept Therapeutics | $81.94 | 2022-2025 | Korlym |
| Grifols USA, LLC | $81.67 | 2025 | Prolastin-C Liquid |
| Upsher-Smith Laboratories LLC | $74.58 | 2021 | |
| Viatris Specialty LLC | $74.41 | 2025 | Yupelri |
| Currax Pharmaceuticals LLC | $73.74 | 2020-2024 | Contrave |
| Biohaven Pharmaceutical Holding Company LTD. | $64.62 | 2022 | |
| Xeris Pharmaceuticals, INC. | $52.70 | 2022-2023 | Gvoke Hypopen |
| Ucb, INC. | $47.56 | 2023-2024 | Nayzilam |
| Alnylam Pharmaceuticals INC. | $41.26 | 2025 | Givlaari |
| Biodelivery Sciences International, INC. | $41.05 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $40.24 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $33.99 | 2021 | |
| Circassia INC. | $31.87 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $29.80 | 2024-2025 | Voquezna |
| Alvogen INC | $29.13 | 2023-2024 | Teriparatide |
| Kowa Pharmaceuticals America, INC. | $27.04 | 2022-2023 | Seglentis, Livalo |
| Vivus LLC | $22.60 | 2024 | Pancreaze |
| Dexcom, INC. | $20.00 | 2022 | |
| Inari Medical, INC. | $19.89 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Adlon Therapeutics L.P. | $19.09 | 2020 | |
| Seqirus USA INC | $19.01 | 2022 | |
| Tris Pharma INC | $18.31 | 2024 | Dyanavel Xr |
| Esperion Therapeutics, INC. | $18.29 | 2024 | Nexletol |
| Biogen, INC. | $16.57 | 2022 | |
| Radius Health, INC. | $16.38 | 2024 | Tymlos |
| Avanir Pharmaceuticals, INC. | $15.97 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.48 | 2023 | Jornay Pm |
| Zyla Life Sciences, INC. | $14.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Raymond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.